Opdivo nivolumab: Additional Phase Ib data

Additional data from 107 Yervoy ipilimumab-naive advanced melanoma patients who were previously treated with 1-5 systemic therapies in the open-label, U.S. Phase Ib CA209-003 trial showed that 0.1, 0.3, 1,

Read the full 304 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE